Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically Ill patients

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Forrest, Alan ^a,g   Garonzik, Samira M ^a   Thamlikitkul, Visanu ^b   Giamarellos Bourboulis, Evangelos J ^c   Paterson, David L ^d   Li, Jian ^e   Silveira, Fernanda P ^f   Nation, Roger L ^e  

^a UNIVERSITY AT BUFFALO   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Acute kidney injury; Colistin; PK TD relationship

Indexed keywords

COLISTIMETHATE; COLISTIN; CREATININE; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; STEADY STATE; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; CRITICAL ILLNESS; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; CREATININE; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 85032507103     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01367-17     Document Type: Article

References (26)

1. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15:225–234. https://doi.org/10.1016/S1473-3099(14)70850-3.
2. Kelesidis T, Falagas ME. 2015. The safety of polymyxin antibiotics. Expert Opin Drug Saf 14:1687–1701. https://doi.org/10.1517/14740338.2015.1088520.
3. Zavascki AP, Nation RL. 2017. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother 61:e02319-16. https://doi.org/10.1128/AAC.02319-16.
4. Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. 2013. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13:380. https://doi.org/10.1186/1471-2334-13-380.
5. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212. https://doi.org/10.1186/cc2872.
6. National Kidney Foundation. 2002. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(Suppl 1):S1–S266.
7. Horcajada JP, Sorli L, Luque S, Benito N, Segura C, Campillo N, Montero M, Esteve E, Mirelis B, Pomar V, Cuquet J, Marti C, Garro P, Grau S. 2016. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. Int J Antimicrob Agents 48:725–727. https://doi.org/10.1016/j.ijantimicag.2016.08.020.
8. Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, Li J, Silveira FP. 2017. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis 64:565–571.
9. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284 –3294. https://doi.org/10.1128/AAC.01733-10.
10. Jelliffe R. 2002. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol 22: 320–324. https://doi.org/10.1159/000065221.
11. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48:1724 –1728. https://doi.org/10.1086/599225.
12. Deryke CA, Crawford AJ, Uddin N, Wallace MR. 2010. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54:4503–4505. https://doi.org/10.1128/AAC.01707-09.
13. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53:879–884. https://doi.org/10.1093/cid/cir611.
14. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. 2012. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 56:2392–2396. https://doi.org/10.1128/AAC.00028-12.
15. Ko H, Jeon M, Choo E, Lee E, Kim T, Jun JB, Gil HW. 2011. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 117:c284–c288. https://doi.org/10.1159/000320746.
16. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. 2011. Risk factors for colistin-associated nephrotoxicity. J Infect 62:187–190. https://doi.org/10.1016/j.jinf.2010.11.013.
17. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. 2014. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43: 349–352. https://doi.org/10.1016/j.ijantimicag.2013.12.002.
18. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57:1300 –1303. https://doi.org/10.1093/cid/cit453.
19. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58:2740–2746. https://doi.org/10.1128/AAC.02476-13.
20. Turkoglu M, Dizbay M, Ciftci A, Aksakal FN, Aygencel G. 2012. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Int J Antimicrob Agents 39:142–145. https://doi.org/10.1016/j.ijantimicag.2011.10.006.
21. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. 2012. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54:1720–1726. https://doi.org/10.1093/cid/cis286.
22. Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Gennaro P, Raponi G, Vitale M, Pietropaoli P, Antonelli M. 2013. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 17:R174. https://doi.org/10.1186/cc12853.
23. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. 2015. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter bau-mannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70:3291–3297.
24. Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Turnidge JD, Forrest A, Silveira FP. 2016. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 62:552–558. https://doi.org/10.1093/cid/civ964.
25. Couet W, Gregoire N, Marchand S, Mimoz O. 2012. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 18:30–39. https://doi.org/10.1111/j.1469-0691.2011.03667.x.
26. Ortwine JK, Sutton JD, Kaye KS, Pogue JM. 2015. Strategies for the safe use of colistin. Expert Rev Anti Infect Ther 13:1237–1247. https://doi.org/10.1586/14787210.2015.1070097.